View Cart  

BioCryst Yanks IND on Hep Drug After FDA Safety Concerns

A A
BioCryst Pharmaceuticals has decided to pull its IND for a new hepatitis C (HCV) drug after the FDA raised concerns about the drug’s toxicity profile.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00